Oncology

NCCN Guidelines Updates

NCCN Guidelines Updates

NCCN Guidelines Updates

NCCN Guidelines Updates

University of Chicago's Comprehensive Cancer Center received $3.9 million from the NCI as the Lead Academic Participating Site for the new NCTN initiative.

MedImmune and Incyte are planning the initiation of a collaborative Phase I/II study to test the efficacy of MedImmune's PD-L1 inhibitor MEDI4736 with Incyte's oral indoleamine dioxygenase-1 (IDO1) inhibitor, INCB24360.

Britain's healthcare cost-effectiveness agency, NICE, has recommended against using Zytiga in chemotherapy-naive prostate cancer patients.

A study published in the journal Breast Cancer Research and Treatment identified increased incidence of triple negative breast cancer in black women compared to white women, while those with Asian heritage were found more susceptible to HER2-positive breast cancer.

Sequenta's ClonoSIGHT that uses next generation sequencing to detect minimal residual disease, provides prognosis on relapse and survival of post-transplant ALL patients.

Having met the primary endpoint of overall survival in it's Phase III trial of TAS-102 for refractory metastatic CRC, Taiho plans regulatory submissions.

ASCO today released new resources to help physicians manage the complications of obesity in patients with cancer and facilitate communication about the importance of weight management and making healthy lifestyle choices following a cancer diagnosis.

Researchers identified tumor-infiltrating CD4+ T cells specific for a mutated antigen expressed by a tumor from a patient with metastatic cholangiocarcinoma. Infusion of this patient with an expanded-population, mutation-specific T cell resulted in tumor regression and stabilization of disease.

The American Cancer Society Cancer Action Network (ACS CAN) initiated an advertising campaign earlier this week to emphasize the importance of federal dollars in the fight against the deadly disease.

Researchers in Canada have developed a model to simulate the cost of active surveillance versus immediate treatment among low-risk prostate cancer patients.

Researchers have identified that other than clogging the arteries, LDL can also promote metastatic cancer cells, which break away from the parent tumor, to reattach at distant site.

Cancer treatments are evolving to work more effectively, but consequently, their costs are rising. In 2013, cancer medicine spending reached $91 billion globally-up from $71 billion in 2008.

The molecular diagnostic testing company Myriad Genetics announced that it had signed a 3-year contract with UnitedHealthcare to make their myRisk cancer susceptibility test accessible to patients.

Merck announced that the FDA has granted a priority review for it's anti-PD-1 antibody, MK-3475, under the accelerated approval program, for the treatment of metastatic melanoma.